Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Guidelines for Writing Outcome01:11

Guidelines for Writing Outcome

3.6K
When developing expected outcomes for a patient care plan, the nurse should adhere to the following recommendations:
Patient outcomes reflect the patient's response to the goal rather than what the nurse aims to achieve. Terminology should be observable and measurable to avoid the reader's interpretation. The desired outcome should be realistic and achievable in the designated care timeframe. Expected outcomes should align with adjunctive therapies. The outcome should enhance care...
3.6K
Nursing Evaluation01:15

Nursing Evaluation

4.1K
The evaluation stage signals the end of the nursing process. The nurse gathers evaluative data to assess whether or not the patient has attained the expected results. Whereas the nurse collects data in the nursing assessment to identify the patient's health concerns, the evaluation stage data determines if the indicated health issues are resolved. Evaluative data collection includes two sections: the data acquired to evaluate patient outcomes and the time criteria for data collection.
4.1K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

291
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
291
Nephrotic Syndrome III : Nursing Management01:24

Nephrotic Syndrome III : Nursing Management

267
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
267
Role of Communication in the Nursing Process III: Evaluation and Documentation01:08

Role of Communication in the Nursing Process III: Evaluation and Documentation

1.9K
A successful patient outcome depends mainly on the evaluation stage of the nursing process. Evaluation determines effectiveness by reviewing what was done previously after the completion of nursing interventions. Every time a healthcare professional steps in or administers treatment, they must reassess or evaluate the action to ensure the intended result. During the evaluation phase, there are three probable patient outcomes:
1.9K
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

319
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
319

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

"More guidelines than rules": reconsidering key gaps in the 2025 American College of Rheumatology treatment recommendations for systemic lupus erythematosus: comment on the article by Sammaritano et al.

Arthritis & rheumatology (Hoboken, N.J.)·2026
Same author

A post hoc analysis of BLISS-LN found Belimumab plus mycophenolate mofetil improves kidney outcomes versus placebo plus mycophenolate mofetil in active lupus nephritis.

Kidney international·2026
Same author

Enpatoran, a Toll-like receptor 7/8 inhibitor, in moderate-to-severe systemic lupus erythematosus: findings from Cohort B of a multicentre, international, double-blind, placebo-controlled dose-finding phase 2 trial.

Lancet (London, England)·2026
Same author

Efficacy and safety of enpatoran, a Toll-like receptor 7/8 inhibitor, in patients with skin manifestations of cutaneous lupus erythematosus or systemic lupus erythematosus: findings from Cohort A of a multicentre, international, double-blind, placebo-controlled, dose-finding phase 2 trial.

The Lancet. Rheumatology·2026
Same author

Systemic lupus erythematosus: Phase 3 clinical trials to watch.

Med (New York, N.Y.)·2026
Same author

Outcome measures in systemic lupus erythematosus.

Current opinion in immunology·2026

Related Experiment Video

Updated: Jan 8, 2026

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
09:43

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

3.4K

Are lupus outcomes improving?

Sumatha Channapatna Suresh1, Richard Furie

  • 1Division of Rheumatology, Northwell, Great Neck, New York, USA.

Current Opinion in Rheumatology
|December 24, 2025
PubMed
Summary

Systemic lupus erythematosus (SLE) patient outcomes have dramatically improved due to new therapies and better management. Early diagnosis and remission are key for preventing organ damage and managing comorbidities.

Keywords:
lupus nephritislupus outcomesmortality trendsremission in systemic lupus erythematosussystemic lupus erythematosussystemic lupus erythematosus damage

More Related Videos

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

Published on: November 1, 2015

18.5K
Three-dimensional Navigation-guided, Prone, Single-position, Lateral Lumbar Interbody Fusion Technique
08:38

Three-dimensional Navigation-guided, Prone, Single-position, Lateral Lumbar Interbody Fusion Technique

Published on: July 15, 2021

3.8K

Related Experiment Videos

Last Updated: Jan 8, 2026

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
09:43

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

3.4K
The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

Published on: November 1, 2015

18.5K
Three-dimensional Navigation-guided, Prone, Single-position, Lateral Lumbar Interbody Fusion Technique
08:38

Three-dimensional Navigation-guided, Prone, Single-position, Lateral Lumbar Interbody Fusion Technique

Published on: July 15, 2021

3.8K

Area of Science:

  • Rheumatology
  • Immunology
  • Internal Medicine

Background:

  • Systemic lupus erythematosus (SLE) management has evolved significantly.
  • Advances in drug discovery and clinical care have improved patient outcomes.

Purpose of the Study:

  • To review the basis for improved long-term outcomes in SLE patients.
  • Analyze organ damage, mortality, healthcare utilization, and quality of life in SLE.

Main Methods:

  • Literature review focusing on SLE outcomes.
  • Analysis of historical and modern patient data.
  • Examination of organ damage progression and mortality rates.

Main Results:

  • Early 20th-century SLE patients had a 7-year survival rate of 50%.
  • Modern SLE management shows significantly improved age-standardized mortality.
  • Comorbidities impacting SLE outcomes are now more actively managed.

Conclusions:

  • The current era offers transformative targeted therapies for SLE.
  • Early diagnosis and achieving remission are crucial for damage prevention.
  • Treat-to-target strategies combined with cardiovascular and metabolic risk management are essential.